Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-03-15 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
监事会决议公告
Annual Report Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 21st meeting of the 4th Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It includes multiple agenda items related to the 2020 Annual Report, audited financial statements, profit distribution proposals, reports on the use of raised funds, internal control self-assessment, and various other corporate governance and financial matters. The document references the 2020 Annual Report and related financial reports multiple times, indicating these reports have been reviewed and approved by the Supervisory Board and will be submitted to the 2020 Annual General Meeting for approval. The document also discusses a proposed 2021 private placement of shares (a capital raising activity), but this is part of the Supervisory Board meeting resolutions rather than a standalone capital/financing update. The document is lengthy (9,906 characters) and contains substantive financial data and detailed discussion of the annual report and financial results, not merely an announcement or a brief summary. Therefore, it is not a report publication announcement or a regulatory filing. The primary focus is on the annual report and related financial statements for the fiscal year 2020, which aligns with the definition of an Annual Report (10-K). FY 2020
2021-03-15 Chinese
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (assurance report) on the "募集资金存放与使用情况专项报告" (special report on the deposit and use of raised funds) for the year 2020 by Tianjin Ruipu Biotechnology Co., Ltd. It includes detailed information about the management, deposit, and use of funds raised through public and non-public stock issuance, with references to regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is a standalone audit/assurance report verifying the special report on raised funds usage, not a full annual report or interim financial report. It contains auditor responsibilities, management responsibilities, audit procedures, and an audit conclusion on the special report. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/assurance report related to a specific regulatory requirement about raised funds usage, not the full annual report or other types of filings. The document length is substantial and contains detailed financial and compliance information, confirming it is not a mere announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-03-15 Chinese
关于举办2020年度网上业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about holding an online performance explanation meeting (业绩说明会) related to the 2020 annual report. It states that the full 2020 annual report and related documents have already been published on the regulatory website. The document invites investors to participate in the online meeting to further understand the annual report and company operations. The document length is short (529 characters) and it does not contain the actual annual report or financial data, but rather announces the event and references the report publication. According to the MENU VS MEAL RULE, this is an announcement about a report and a meeting, not the report itself. Therefore, the appropriate classification is Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financials and company performance.
2021-03-15 Chinese
2021年度向特定对象发行股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report for a private placement of shares by Tianjin Ringpu Biotechnology Co., Ltd. It extensively discusses the use of raised funds, investment projects, company background, industry and policy context, and financial impacts. The content focuses on capital raising and the use of proceeds for specific projects, including production capacity expansion and R&D upgrades. There are no financial statements or quarterly/yearly financial results presented, nor is this a regulatory announcement or a brief summary. The document is not an earnings release, annual report, or management discussion but rather a capital/financing update related to a specific fundraising event and the use of proceeds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-03-15 Chinese
2021年度向特定对象发行股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed analysis report regarding a 2021 private placement of shares by Tianjin Ringpu Biotechnology Co., Ltd. It discusses the background, purpose, legal compliance, pricing, and impact of the issuance of new shares to specific investors. The content focuses on the company's capital raising through a non-public issuance of shares to specific investors, including regulatory compliance and financial impact analysis. There is no indication that this is an earnings release, annual report, or other financial statement. Instead, it is a capital/financing update related to a private placement of shares. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is substantial and contains detailed financial and regulatory information about the financing activity, supporting a high confidence level.
2021-03-15 Chinese
内幕信息知情人登记备案制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document from Tianjin Ringpu Bio-technology Co., Ltd regarding the registration and management system for insiders who have access to material non-public information (insider information). It outlines definitions, scope, responsibilities, procedures for insider information management, confidentiality, and penalties for violations. The document references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a financial report, earnings release, or announcement of voting results. It is not a report publication announcement or a certification. It is a governance-related document detailing internal rules and procedures for managing insider information and compliance with securities laws. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7667 characters) and content support this classification with high confidence.
2021-03-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.